LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 20, 2005--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that it has initiated two definitive pharmacokinetic studies comparing the bioavailability of zileuton controlled-release (CR) tablets and zileuton immediate-release (IR) tablets (ZYFLO(R)) in healthy volunteers. The first is a single-dose study designed to compare the bioavailability of zileuton CR administered under fasting and non-fasting conditions with zileuton IR under fasting conditions. Investigators expect to enroll 24 volunteers in this randomized, single-center, three-period crossover study. Dosing began December 10, 2005 and should be completed by mid-January 2006. Data is expected by the end of the first quarter of 2006.
